. Author manuscript; available in PMC: 2016 Jun 1.

Published in final edited form as: Cancer Discov. 2015 Oct 29;5(12):1282–1295. doi: 10.1158/2159-8290.CD-15-1020

Table 1. Sumary of human B-ALL samples.

Sample	Prior anti-CD19Tx	Time to relapse/ progression	Surface CD19(FC)	CNA analysis by WES(Chrl6)	DNA-seq CD19 exl-14	VAF in DNA	RNA-seq CD19 exl-15	VAF in RNA
CHOP101	Blinatumomab	N/A	+	INTACT	WT	NOT DETECTED	WT	NOT DETECTED
CHOP101R	CART-19	2 mos	-	INTACT	WT	>50%	WT	>75
					G67fs	28% (13/47)	G67fs	29% (52/178)
					P204fs	15% (10/66)	P204fs	5% (8/172)
CHOP105R1	Failed CART-19	8 mos	+	INTACT	WT	0%(0/21)	WllldelinsWPLR	0.4% (1/246)
CHOP105R2	CART-19	14 mos (8+6)	-	Hemizygous del(16) (pl3.11pll.l)	DELETED	N/A	Deletion	N/A
CHOP105R2	CART-19	14 mos (8+6)	-	Hemizygous del(16) (pl3.11pll.l)	W111delinsWPLR	100% (22/22)	W111delinsWPLR	100% (102/102)
CHOP107Ra	CART-19	9 mos	-	WT	WT	NOT DETECTED	WT	NOT DETECTED
CHOP107Rb (also reported as NIH6614)	CART-19	10 mos (9+1)		WT	WT	NOT DETECTED	ND	NOT DETECTED
CHOP133R	CART-19	2 mos	-	Hemizygous del(16)	LOH	N/A	LOH	N/A
CHOP133R	CART-19	2 mos	-	Hemizygous del(16)	GlOOfs	100% (34/34)	GlOOfs	100% (38/38)

NOTE: Pre–CART-19 samples are highlighted in gray.

Abbreviations: Ex, exon; FC, flow cytometry; fs, frameshift mutation after indicated amino acids; mos, months; N/A, not applicable; seq, sequencing; Tx, therapy; VAF, variant allele frequency;

W111delinsWPLR, insertion of three amino acids (PLR) after W-111; WT, wild-type.